投资收益“断崖式”退潮,上海医药上半年净利润下滑超两成,应收账款逼近千亿元

深圳商报·读创
Sep 02

深圳商报·读创客户端记者张弛  近日,上海医药集团股份有限公司(601607.SH/02607.HK)披露的2026年半年度报告显示,公司上半年实现营业收入1474.70亿元,同比增长4.15%;实现归属于上市公司股东的净利润35.04亿元,同比下降21.40%;基本每股收益0.95元,同比下降20.83%。  值得关注的是,在归母净利润显著下滑的同时,公司扣除非经常性损益后的净利润达到24.77...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10